Business
SAB Biotherapeutics Presents Positive IND-Enabling GLP Toxicology Study for SAB-142, a Novel Immunotherapeutic for Type 1 Diabetes at FOCIS 2023
SAB highlights results from GLP toxicology study confirming SAB-142's mechanism of action at the 23rd Federation of Clinical Immunology Societies (FOCIS)
About this update from Sab Biotherapeutics, Inc.
[{"type":"text","content":"SAB highlights results from GLP toxicology study confirming SAB-142's mechanism of action at the 23rd Federation of Clinical Immunology Societies (FOCIS) Study shows SAB’s fully-human multi-target immune modulating therapeutic for treatment of Type 1 Diabetes is well tolerated SIOUX FALLS, S.D., June 21, 2023 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS), (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that produces specifically targeted, high-potency, fully-human multi-target immunoglobulin (hIgG) antibodies (fully-human polyclonal antibodies) without the need for human donors, today announced the presentation of positive safety and pharmacologic data from a GLP toxicology study for SAB-142, a first in class fully human immunotherapeutic being developed for delaying onset and progression of Type 1 Diabetes (T1D), at the Federation of Clinical Immunology Societies (FOCIS) in Boston. Results from the IND-enabling GLP tox study confirmed that SAB-142 affects the same subsets of immune cells associated with T1D as commercially available rabbit-derived anti-thymocyte globulin (rATG) in vivo. SAB-142 is a first-in-class fully-human, multi-target anti-thymocyte immunoglobulin treatment aimed to provide a superior profile for delaying onset or progression of T1D. SAB-142's unique multi-target strategy can be directed at the multiple immunological cell subsets associated with T1D and other autoimmune diseases. Another anti-thymocyte product produced in rabbits and FDA-approved for kidney transplantation, rATG, was investigated in patients with Type 1 Diabetes and showed significant efficacy in delaying progression of the disease by preserving C-peptide levels, a surrogate measure for endogenous insulin production by pancreatic beta cells. Commercially available products for T-cell mediated autoimmune diseases, such as fully-animal antibodies often induce immune-mediated reactions such as serum sickness. By contrast, SAB-142, which is a fully-human polyclonal antibody therapeutic, may be administered multiple times without causing these immune-related adverse reactions, which is particularly desirable for patients with lifelong diseases such as T1D. Taking place June 20-23, 2023, in Boston, the FOCIS 2023 Annual Meeting is a leading translational immunology conference that explores research ...